findmyKOL
Clinical trialNCT03918252Active, not recruitingPhase 2Interventional

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

SponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrollment30Mesothelioma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard bi-/tri-modality therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Greenebaum Comprehensive Cancer Center University of Maryland School of Medicine

    Baltimore, Maryland, United States

  • Johns Hopkins University

    Baltimore, Maryland, United States

  • University of Texas M.D. Anderson Cancer Center

    Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ipilimumab →Nivolumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Oct 2019
Primary completion
30 Jun 2027
Completion
30 Jun 2028
Last update posted
5 Jun 2026
Registered enrollment
30
Registry id
NCT03918252
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.